Online Access Free RAC-GS Exam Questions

What is the LAST stage in the development of a quality risk management process for a medical device?

• A.Risk analysis
• B.Risk acceptance
• C.Risk reduction
• D.Risk evaluation

According to ICH, which of the following components of study information is NOT required in a clinical study report?

• A.Detailed CVofall investigators
• B.Protocol and protocol amendments
• C.ListoflECsorlRBs
• D.Randomization scheme and codes

As a member of the product launch review committee, a regulatory affairs professional discovers a major issue with the labeling of a product prior to production. In addition to informing the committee, which is the BEST approach to address the issue?

• A.Correct the label text.
• B.Inform the regulatory authorities.
• C.Abort the product launch.
• D.Delay the start of product production.

A company is developing a new product for the global market. A new international guideline will recommend relevant studies in the pediatric population, and the guideline will be effective before the approval of the company's new product.
What is the BEST advice the regulatory affairs professional can provide to minimize the impact of this guideline on the successful registration of the new product?

• A.The new guideline has no impact on the current registration plan since all relevant registration studies are almost completed.
• B.The company should consult with relevant regulatory authorities to determine the potential impact on the current registration plan.
• C.The company should initiate the required pediatric studies immediately to avoid costly delays to the current registration plan.
• D.The new guideline has no impact on the current registration plan, but the company must be prepared to defend its decision.

When applying for marketing approval of a drug for a rare disease, which requirement can be waived?

• A.Phase III clinical trials
• B.Phase I clinical trials
• C.Pre-clinical studies
• D.Phase I and II clinical trials